Results 191 to 200 of about 191,032 (247)

An open-label study on the safety and immunogenicity of a PD-1-enhanced DNA vaccine used as a T cell booster for COVID-19. [PDF]

open access: yesEBioMedicine
Wong YC   +12 more
europepmc   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia   +4 more
wiley   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang   +5 more
wiley   +1 more source

Skin patch delivery of a SARS-CoV-2 spike DNA vaccine produces broad neutralising antibody responses. [PDF]

open access: yesHeliyon
McMillan CLD   +13 more
europepmc   +1 more source

Extended HPV typing as an efficient alternative within HPV‐based screening programs

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Extended high‐risk human papillomavirus (hrHPV) typing holds promise for improving cervical intraepithelial neoplasia grade 3 (CIN3) detection, particularly as vaccinated cohorts may shift the prevalence of oncogenic HPV types. The authors of this study evaluated extended hrHPV genotyping within a public screening program involving women ...
Joacim Meneses‐León   +11 more
wiley   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

open access: yesiMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen   +4 more
wiley   +1 more source

A large‐scale single‐cell transcriptomic atlas indicates the immune panorama of influenza A infection

open access: yesiMeta, EarlyView.
The study presents a large‐scale single‐cell transcriptomic atlas profiling over 612,010 peripheral immune cells from 97 individuals to decode the heterogeneity of influenza infection. These findings indicate a fundamental immune dichotomy determining clinical trajectories: a protective, monocyte‐centric antiviral state in mild disease versus a ...
Yi Wang   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy